Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novartis Previews Panobinostat PFS Advantage In Myeloma

Dec 17 2013

• By Mary Jo Laffler

Related Content

As Sun Sets On <em>Gleevec</em>, Novartis Looks To New Horizons In Oncology

Nov 19 2012

Epigenetic Modifiers Take Center Stage, Big Pharma Takes Notice

Apr 16 2012

Epigenetics At The Epicenter Of Oncology Drug Discovery At AACR

Apr 04 2013

HDAC Inhibitor Mysteries Remain As Candidates Advance

Dec 01 2011

Oncology NDAs Based On Single-Arm Studies Run Risk Of FDA Refusal To File

May 01 2011

Related Companies

Novartis AG

Merck & Co., Inc.

Johnson & Johnson

Additional Topics

Research & Development Clinical Trials BioPharmaceutical

More from R&D

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window